Related Experiment Video
Updated: Apr 3, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
The FOCUS4 design for biomarker stratified trials
1Medical Research Council Clinical Trials Unit, University College London, 125 Kingsway, London WC2B 6NH, UK. r.kaplan@ucl.ac.uk.
Abstract:
Randomised clinical trials (RCTs) remain the gold standard of evidence for the benefit of new therapeutics but standard designs fit awkwardly with key developments in biomarker-stratified drug development. Firstly, the unprecedented number of new agents being developed in oncology (usually with specific targets for which there may be predictive biomarkers) mandates a need for new trial designs that are more efficient in screening out new agents with modest likelihood of benefit, concentrating resources on the most promising ones. The multi-arm multi-stage (MAMS) design developed some years ago addresses this need. Secondly, biomarker-stratified trials, when tackled one biomarker/drug pairing at a time, are inherently highly inefficient. The FOCUS4 trial design was developed to overcome this problem, using a platform that incorporates multiple parallel biomarker-stratified RCTs in individual cohorts, and capable of adapting its design in response to developing evidence.
Insights
New clinical trial designs are essential for efficient oncology drug development. The multi-arm multi-stage (MAMS) and FOCUS4 designs improve screening of new therapeutics and biomarker-stratified trials.
Area of Science:
- Oncology
- Clinical Trial Design
- Biomarker Development
Background:
- Randomised clinical trials (RCTs) are the gold standard but standard designs are inefficient for modern drug development.
- The increasing number of targeted oncology agents necessitates more efficient trial designs.
- Biomarker-stratified trials, when conducted individually, are highly inefficient.
Purpose of the Study:
- To introduce and discuss advanced clinical trial designs tailored for oncology.
- To address the inefficiencies in screening new therapeutic agents and biomarker-stratified trials.
- To present the Multi-Arm Multi-Stage (MAMS) and FOCUS4 trial designs as solutions.
Main Methods:
- The Multi-Arm Multi-Stage (MAMS) design allows for early stopping of unpromising agents.
- The FOCUS4 trial design employs a platform for multiple parallel biomarker-stratified RCTs.
- Adaptive design capabilities allow for modifications based on accumulating evidence.
Main Results:
- MAMS designs efficiently screen multiple agents, concentrating resources on promising candidates.
- The FOCUS4 platform enhances efficiency by integrating multiple biomarker-drug pairings.
- Adaptive designs improve the responsiveness of trials to emerging data.
Conclusions:
- Advanced trial designs like MAMS and FOCUS4 are crucial for efficient oncology drug development.
- These designs optimize resource allocation by focusing on agents with higher likelihoods of benefit.
- Implementing adaptive strategies in biomarker-stratified trials leads to more effective drug development pipelines.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Study Design in Statistics
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...

